
    
      This clinical trial is a single centre Phase I study, with a single dose, non-randomized,
      open-label, uncontrolled design.

      A total of 8 subjects will be included in the study.

      It will aim to assess the absolute bioavailability, the mass balance and routes of
      elimination of CHF6001 in male healthy volunteers, using [14C]-radiolabelled drug substance
      administered as an intravenous (IV) infusion concomitantly to an inhaled non-radiolabelled
      dose.

      Standard safety assessments will be conducted during the Study, including safety blood and
      urine laboratory tests, vital signs, physical examinations, ECGs and observations of any
      adverse events. Blood, urine and feces samples will be also collected for PK analysis.
    
  